Artiva to discontinue cell therapy after two patient deaths, cut workforce by 94%

What happened

Artiva Biotherapeutics said it will halt development of its lead experimental cell therapy, AlloNK, after two patient deaths, cut its workforce by about 94%, and evaluate strategic alternatives. The company's shares slumped 32%.

Confirmed

Global impact / market context

Stopping the lead therapy removes the company's main potential revenue source, which means the business has less chance to earn money from its pipeline. Cutting 94% of staff shrinks costs, and the 32% share drop shows investors saw the news as a serious loss of value.

Confirmed

An analyst said the therapy path carried too much risk, uncertainty, and an incredibly high cost of capital, which means borrowing money would be expensive. Artiva had about $319.1 million in cash as of September 30, money it can use while it evaluates strategic alternatives.

Analyst inference

What to watch

1. Artiva had about $319.1 million in cash, cash equivalents, and investments as of September 30; investors can watch how long this cash available lasts as the company evaluates strategic alternatives. Confirmed
2. The company plans to cut its workforce by about 94%, so watch for details on the timing and cost of the job cuts and how many employees remain. Proposed
3. Watch for any announced strategic alternatives, such as a sale or partnership, because that could change the outlook for the remaining business and its shares. Analyst inference

Evidence

• Original source link unavailable